Literature DB >> 11205744

Differences in early and late responses between neurotrophin-stimulated trkA- and trkC-transfected SH-SY5Y neuroblastoma cells.

A Edsjö1, B Hallberg, S Fagerström, C Larsson, H Axelson, S Påhlman.   

Abstract

Despite their sympathetic neuroblast origin, highly malignant neuroblastoma tumors and derived cell lines have no or low expression of the neurotrophin receptor genes, trkA and trkC. Expression of exogenous trkA in neuroblastoma cells restores their ability to differentiate in response to nerve growth factor (NGF). Here we show that stable expression of trkC in SH-SY5Y neuroblastoma cells resulted in morphological and biochemical differentiation upon treatment with neurotrophin-3 (NT-3). To some extent, trkA- and trkC-transfected SH-SY5Y (SH-SY5Y/trkA and SH-SY5Y/trkC) cells resembled one another in terms of early signaling events and neuronal marker gene expression, but important differences were observed. Although induced Erk 1/2 and Akt/PKB phosphorylation was stronger in NT-3-stimulated SH-Y5Y/trkC cells, activation of the immediate-early genes tested was more prominent in NGF-treated SH-SY5Y/ trkA cells. In particular, c-fos was not induced in the SH-SY5Y/trkC cells. There were also phenotypic differences. The concentrations of norepinephrine, the major sympathetic neurotransmitter, and growth cone-located synaptophysin, a neurosecretory granule protein, were increased in NGF-treated SH-SY5Y/trkA but not in NT-3-treated SH-SY5Y/trkC cells. Our data suggest that NT-3/p145trkC and NGF/p140trkA signaling differ in some aspects in neuroblasoma cells, and that this may explain the phenotypic differences seen in the long-term neurotrophin-treated cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11205744

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  8 in total

1.  Integrin alpha9 beta1 is a receptor for nerve growth factor and other neurotrophins.

Authors:  Izabela Staniszewska; Ilker K Sariyer; Shimon Lecht; Meghan C Brown; Erin M Walsh; George P Tuszynski; Mahmut Safak; Philip Lazarovici; Cezary Marcinkiewicz
Journal:  J Cell Sci       Date:  2008-01-29       Impact factor: 5.285

2.  Neurotrophin effects on neuroblastoma cells: correlation with trk and p75NTR expression and influence of Trk receptor bodies.

Authors:  M E Evangelopoulos; J Weis; A Kruttgen
Journal:  J Neurooncol       Date:  2004-01       Impact factor: 4.130

3.  Nerve growth factor regulates synaptophysin expression in developing trigeminal ganglion neurons in vitro.

Authors:  L Tarsa; A Balkowiec
Journal:  Neuropeptides       Date:  2008-11-18       Impact factor: 3.286

4.  Caffeic Acid Phenethyl Ester (CAPE) Protects PC12 Cells from Cisplatin-Induced Neurotoxicity by Activating the NGF-Signaling Pathway.

Authors:  Rafaela Scalco Ferreira; Neife Aparecida Guinaim Dos Santos; Nádia Maria Martins; Laís Silva Fernandes; Antonio Cardozo Dos Santos
Journal:  Neurotox Res       Date:  2017-12-19       Impact factor: 3.911

5.  Abnormal sympathetic nervous system development and physiological dysautonomia in Egr3-deficient mice.

Authors:  Laurie C Eldredge; Xiaoguang M Gao; David H Quach; Lin Li; Xiaoqiang Han; Jon Lomasney; Warren G Tourtellotte
Journal:  Development       Date:  2008-07-24       Impact factor: 6.868

6.  Positional and functional mapping of a neuroblastoma differentiation gene on chromosome 11.

Authors:  Katleen De Preter; Jo Vandesompele; Björn Menten; Philippa Carr; Heike Fiegler; Anders Edsjö; Nigel P Carter; Nurten Yigit; Wim Waelput; Nadine Van Roy; Scott Bader; Sven Påhlman; Frank Speleman
Journal:  BMC Genomics       Date:  2005-07-06       Impact factor: 3.969

7.  Neuroblastoma patient-derived xenograft cells cultured in stem-cell promoting medium retain tumorigenic and metastatic capacities but differentiate in serum.

Authors:  Camilla U Persson; Kristoffer von Stedingk; Daniel Bexell; My Merselius; Noémie Braekeveldt; David Gisselsson; Marie Arsenian-Henriksson; Sven Påhlman; Caroline Wigerup
Journal:  Sci Rep       Date:  2017-08-31       Impact factor: 4.379

Review 8.  Inhibiting TRK Proteins in Clinical Cancer Therapy.

Authors:  Allison M Lange; Hui-Wen Lo
Journal:  Cancers (Basel)       Date:  2018-04-04       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.